Home Cart Sign in  
Chemical Structure| 873697-71-3 Chemical Structure| 873697-71-3

Structure of Omecamtiv mecarbil
CAS No.: 873697-71-3

Chemical Structure| 873697-71-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Omecamtiv mecarbil is a selective sarcomere-directed cardiac myosin activator with an EC50 of 0.6 μM.

Synonyms: CK-1827452

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Omecamtiv mecarbil

CAS No. :873697-71-3
Formula : C20H24FN5O3
M.W : 401.43
SMILES Code : O=C(N1CCN(CC2=CC=CC(NC(NC3=CC=C(C)N=C3)=O)=C2F)CC1)OC
Synonyms :
CK-1827452
MDL No. :MFCD18633260
InChI Key :RFUBTTPMWSKEIW-UHFFFAOYSA-N
Pubchem ID :11689883

Safety of Omecamtiv mecarbil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Omecamtiv mecarbil

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C2C12 myoblasts 10–100 µg/mL 2 minutes Measurement of in vitro gliding filament motility of human β-cardiac HMM was done as previously described. R712L-myosin propelled actin filaments more slowly than WT-myosin at all concentrations tested. PMC7895523
human permeabilized cardiomyocytes 1 µM OM increased force production at low calcium levels, slowed the kinetics of contractions and relaxations, and evoked an oscillation between normal and reduced intracellular Ca2+ transients, action potential lengths, and contractions. PMC8041714
isolated canine cardiomyocytes 1 µM 10 minutes OM increased the stiffness of unloaded cardiomyocytes, reduced diastolic length, and evoked an oscillation between normal and reduced contractions at higher stimulation frequencies. PMC8041714

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
rats Wistar-Kyoto rats intravenous 600-1200 µg/kg cumulative dose, duration not specified OM improved cardiac systolic function but evoked diastolic dysfunction and transient electromechanical alternans. PMC8041714

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01077167 Heart Failure PHASE2 WITHDRAWN 2025-05-11 -
NCT04464525 Chronic Heart Failure With Red... More >>uced Ejection Fraction Less << PHASE3 WITHDRAWN 2026-11-27 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.49mL

0.50mL

0.25mL

12.46mL

2.49mL

1.25mL

24.91mL

4.98mL

2.49mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories